{"organizations": ["Exelixis Drugs Score"], "uuid": "a708a9c384e390bbbfdfe310b9ce4ca406645a5e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.investors.com", "main_image": "http://www.investors.com/image/IT12-BMY-0721-company.jpg.cms", "site_section": "http://finance.yahoo.com/rss/headline?s=NVS", "section_title": "Yahoo! Finance: NVS News", "url": "http://news.investors.com/072015-762375-bmy-exel-stocks-rise-on-kidney-cancer-data.htm?ven=yahoocp&src=aurlled&ven=yahoo", "country": "US", "title": "Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer", "performance_score": 0, "site": "investors.com", "participants_count": 0, "title_full": "Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer", "spam_score": 0.0, "site_type": "news", "published": "2015-07-20T17:50:00.000+03:00", "replies_count": 0, "uuid": "a708a9c384e390bbbfdfe310b9ce4ca406645a5e"}, "author": "", "url": "http://news.investors.com/072015-762375-bmy-exel-stocks-rise-on-kidney-cancer-data.htm?ven=yahoocp&src=aurlled&ven=yahoo", "ord_in_thread": 0, "title": "Bristol-Myers, Exelixis Drugs Score Vs. Kidney Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "6 Big-Cap Drugmakers Reporting Earnings Next Week \nNext week will bring a passel of earnings reports from large-cap drugmakers, as both biotech and pharma stocks are trading at new highs yet again. Novartis, Bristol-Myers Squibb, Eli Lilly, Valeant Pharmaceuticals, AbbVie and Biogen are all on tap in a busy earnings week. Here's a quick rundown: ... 07/18/2015 08:02 AM ET What Will Gilead Buy Next? 4 Possible Targets \nTuesday's announcement that Celgene (NASDAQ:CELG) agreed to acquire Receptos (NASDAQ:RCPT) pleased investors in those two stocks, but for investors in Gilead Sciences (NASDAQ:GILD), which was rumored to be interested in Receptos, it means waiting on the edges of their seats. \"Literally the only ... 07/15/2015 04:44 PM ET Momenta Downgraded After Stock Price Doubles \nMomenta Pharmaceuticals' (NASDAQ:MNTA) stock dropped 8% Thursday after UBS downgraded it to sell, saying the company's recent good news has already been priced into the stock. Analyst Marc Goodman wrote that last month's launch of Momenta's and partner Novartis' (NYSE:NVS) generic version of Teva ... 07/02/2015 12:11 PM ET Biogen, AGTC Link Up To Develop Gene Therapy \nBiotech Applied Genetic Technologies Corp. (NASDAQ:AGTC) inked a gene-therapy collaboration with Biogen (NASDAQ:BIIB) that could be worth more than $1 billion, sending Applied Genetic stock soaring in massive volume. Biogen will pay $124 million upfront, including a $30 million purchase of AGTC ... 07/02/2015 11:28 AM ET Can Hepatitis B Be A Blockbuster Bug? \nThe new class of hepatitis C drugs, led by Gilead Sciences (NASDAQ:GILD) and AbbVie (NYSE:ABBV), has turned into one of the biggest success stories in biotech history. Yet hepatitis C is one of only five viruses that cause viral hepatitis. Do any of the others have such lucrative potential? One ... 07/01/2015 08:02 AM ET Spam Email Declines, But New Malware Threats Rise \nUnsolicited commercial email, or spam, accounted for 49.7% of all email in June. While still a lot, June marked the first time in over a decade that the spam rate has fallen below 50%, Internet security firm Symantec (NASDAQ:SYMC) said in its June report on cybersecurity. The last time the ... 06:00 PM ET IBM EPS Beats, Sales Miss Second Straight Quarter \nIBM (NYSE:IBM) late Monday posted mixed Q2 earnings similar to Q1, as earnings per share minus items solidly beat Wall Street expectations but revenue missed. The company said year-over-year revenue rose more than 20% for what it calls its \"strategic initiatives,\" including more than 50% for its ... 04:45 PM ET SunEdison Will Buy Vivint Solar, Eyes Alt-Energy Crown \nSunEdison (NYSE:SUNE) announced Monday that it will acquire No. 2 residential installer Vivint Solar (NYSE:VSLR) for about $2.2 billion in cash, stock and notes, the latest of several multibillion-dollar deals that are part of its aggressive strategy to become one of the world's top alternative ... 04:21 PM ET China Phone Makers Gain, 'Receding' iPhone Demand? \nChinese mobile phone makers gained share vs. Apple (NASDAQ:AAPL) in June amid what Bernstein Research described as possible \"receding iPhone momentum,\" and overall smartphone shipments fell 15% from the previous month, according to figures released by the China Academy of Telecommunication ... 04:00 PM ET Apple analysts place their Q3 bets before windows close \nWall Street analysts on Monday made last-minute tweaks to their Apple (NASDAQ:AAPL) financial models ahead of the company's fiscal third-quarter report, due after the market close Tuesday. The most important question for Apple's results is how iPhone sales did in Q3, since smartphones represent the ... 03:45 PM ET", "external_links": [], "published": "2015-07-20T17:50:00.000+03:00", "crawled": "2015-07-21T01:18:16.088+03:00", "highlightTitle": ""}